Table 4.
Comparison of Cumulative Risk of Isolated Hematologic Relapse or Any Relapse Between Patients With BCR-ABL1–Like ALL or Other B-ALL, According to Final Risk Group
| Risk Group* | No. of Patients | % Cumulative Risk of Isolated Hematologic Relapse (± SE) |
% Cumulative Risk of Any Relapse (± SE) |
||||
|---|---|---|---|---|---|---|---|
| Year 5 | Year 10 | P | Year 5 | Year 10 | P | ||
| Low | |||||||
| BCR-ABL1–like | 16 | 0 | 6.7 ± 6.7 | .46 | 0 | 14.4 ± 9.9 | .23 |
| Other B-ALL | 178 | 1.7 ± 1.0 | 4.2 ± 2.2 | 4.0 ± 1.5 | 6.4 ± 2.4 | ||
| Standard | |||||||
| BCR-ABL1–like | 18 | 5.6 ± 5.6 | 5.6 ± 5.6 | .58 | 11.1 ± 7.6 | 11.1 ± 7.6 | .74 |
| Other B-ALL | 109 | 9.3 ± 2.8 | 9.3 ± 2.8 | 13.9 ± 3.4 | 13.9 ± 3.4 | ||
| High | |||||||
| BCR-ABL1–like | 5 | 0 | 0 | .28 | 0 | 0 | .11 |
| Other B-ALL | 15 | 21.3 ± 11.6 | 21.3 ± 11.6 | 42.0 ± 13.9 | 42.0 ± 13.9 | ||
Abbreviations: ALL, acute lymphoblastic leukemia; B-ALL, B-cell ALL.
*
Based on minimal residual disease levels measured on days 19 and 46 of remission induction.